Wyniki wyszukiwania

1

Immunosuppressive activity of C-terminal fragments of tachykinins

100%

Siemion I. Z., Kubik A., Zimecki M., Wieczorek Z.

Archivum Immunologiae et Therapiae Experimentalis

|

1994

|

tom 42

|

nr 3

2

The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome

72%

Szymaszkiewicz A., Malkiewicz A., Storr M., Fichna J., Zielinska M.

Journal of Physiology and Pharmacology

|

2019

|

tom 70

|

nr 1

3

Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists

72%

Juszczak M., Boczek-Leszczyk E.

Journal of Physiology and Pharmacology

|

2008

|

tom 59

|

nr 3

553-562

The aim of the present study was to investigate the effect of peptide NK-1 and NK-2 receptors agonists and antagonists (and their natural ligands, i.e., substance P and neurokinin A) on the oxytocin (OT) secretion from the rat neurohypophysis into the blood. Intracerebroventricular (icv) injection of substance P (SP) or highly selective NK-1 receptor agonist - [(Sar9,Met(O2)11)-Substance P] - significantly stimulated the OT secretion from the rat neurohypophysis into the general circulation. After icv injection of the NK-1 receptor antagonist - [(Tyr6,D-Phe7,D-His9)-Substance P (6-11)] - the blood plasma OT concentration was significantly lower, when compared to vehicle-injected animals. On the other hand, the icv administered neurokinin A (NKA) and the NK-2 receptor agonist - [(ß-Ala8)-Neurokinin A (4-10)] - were essentially inactive in modifying OT secretion. However, such injection of the NK-2 receptor antagonist - [(Tyr5,D-Trp6,8,9,Lys-NH210)-Neurokinin A (4-10)] - was found to diminish the blood plasma hormone concentration, when compared to vehicle-injected animals. The neurohypophysial content of OT was decreased in NKA-treated rats, but neither the NK-2 receptor agonist nor antagonist were able to affect the OT output from the rat posterior pituitary. The hypothalamic levels of OT were not modified by any of the studied peptides. The present data strongly indicate a major role for the tachykinin NK-1 receptor in SP- and/or NKA-dependent regulation of OT secretion from the rat neurohypophysis into the blood.

4

Activation of tachykinin system in the pedunculopontine tegmental nucleus suppresses hippocampal theta rhythm in urethane-anesthetized rats

72%

Leszkowicz E., Trojniar W.

Acta Neurobiologiae Experimentalis

|

2005

|

tom 65

|

nr 4

5

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Role of tachykinins in the control of pancreatic secretion and circulation

72%

Pawlik W. W., Konturek S. J., Gustaw P., Czarnobilski K., Sendur R., Jaworek J., Yanaihara N.

Journal of Physiology and Pharmacology

|

1992

|

tom 43

|

nr 1

Tachykinins (TK) are family of peptides including substance P (SP), substance K (SK) and neuromedin K (NK) that have been found in the nerves of the gastrointestinal tract and proposed to act as neurotransmitters to affect the motor, secretory and circulatory functions of the gut, but little is known about their action on the pancreas. In this study three series of tests were carried out to determine the action of SP, SK and NK on pancreatic secretion in conScious dogs and amylase release from the dispersed rat pancreatic acini and to correlate the alterations in pancreatic secretory and circulatory effects of TK in anesthetized dogs. SP, SK and NK infused i. v. in graded doses (0.12-1.0 µg/kg per h) in conscious dogs stimulated pancreatic protein outputs reaching, respectively, 38% and 23% of the maximal response to CCK (40 pmol/kg per h). HCO₃ outputs were also significantly increased but the highest response did not exceed about 5% of secretin (328 pmol/kg per h) maximum. Cholinergic blockade by atropine abolished the pancreatic responses to tachykinins. When added at various concentrations (10⁻¹¹ -10⁻⁷ M) to the incubation medium of rat dispersed pancreatic acini, SK, SP and NK increased in concentration-dependent manner the release of amylase from the resting pancreatic acini and augmented the enzyme release induced by CCK-8 and by urecholine. In anesthetized dogs infused with a background dose of secretin (82 pmol/kg per h), addition of SP, SK and NK caused an immediate and dose-dependent increase in the pancreatic blood flow, oxygen consumption and pancreatic secretion accompanied by a dose-dependent decrease in arterial blood pressure. This study shows that TK are potent pancreatic circulatory stimulants and moderate secretagogues both in vivo and in vitro, acting, at least in part, via cholinergic pathway.

6

Effect of a non-peptide NK-2 tachykinin receptor antagonist on LH, FSH, and prolactin release by rat hemipituitaries in vitro

58%

Debeljuk L., Bandera R., Bartke A.

Journal of Physiology and Pharmacology

|

1997

|

tom 48

|

nr 3

7

Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies

58%

Juszczak M., Boczek-Leszczyk E., Stempniak B.

Journal of Physiology and Pharmacology

|

2007

|

tom 58

|

nr 4

The aim of the present study was to investigate the influence of melatonin on vasopressin (AVP) release from the rat hypothalamo-neurohypophysial (H-NH) system, both in vivo and in vitro, possibly modified by the peptide NK-1 and/or NK-2 receptor agonists and antagonists. Highly selective NK-1 receptor agonist, i.e., [Sar9,Met(O2)11]-Substance P, has been shown to enhance the AVP release from isolated rat H-NH system in vitro, while the NK-1 receptor antagonist - (Tyr6,D-Phe7,D-His9)-Substance P (6-11) as well as the NK-2 receptor selective agonist - (ß-Ala8)-Neurokinin A (4-10) and antagonist - (Tyr5,D-Trp6,8,9,Lys-NH210)-Neurokinin A (4-10) were essentially inactive in modifying AVP secretion. Melatonin inhibited basal release of AVP but was not able to reduce significantly the in vitro response of vasopressinergic neurones to NK-1 receptor agonist. After intracerebroventricular (icv) administration, substance P (SP), neurokinin A (NKA) and the NK-1 receptor agonist (all at the concentration of 10-7 M/L) significantly enhanced plasma AVP concentration. Such stimulatory effect of the latter peptide on AVP output from the neurohypophysis was reduced by an intravenous (iv) injection of melatonin, which itself (at a concentration of 5 ng/ml) caused a significant decrease in AVP release 10 min after injection. The inhibitory influence of melatonin on the AVP secretion was absent in rats injected icv with both tachykinin receptors antagonists, the NK-2 receptor agonist or NKA. The present data indicate a distinct role for NK-1 receptor in NKA/SP-mediated regulation of AVP release from the rat H-NH system. They have also shown that, under present experimental conditions, the stimulatory effect of NK-1 receptor activation on AVP secretion into the blood is sensitive to inhibitory influence of melatonin.

Ograniczanie wyników

Immunosuppressive activity of C-terminal fragments of tachykinins

The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome

Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists

Activation of tachykinin system in the pedunculopontine tegmental nucleus suppresses hippocampal theta rhythm in urethane-anesthetized rats

Role of tachykinins in the control of pancreatic secretion and circulation

Effect of a non-peptide NK-2 tachykinin receptor antagonist on LH, FSH, and prolactin release by rat hemipituitaries in vitro

Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies